apl. Prof. Dr. Lucie Heinzerling



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Serositis in Association with System Therapy with Checkpoint Inhibitors - More frequent than thought? - An Evaluation of the SERIO Adverse Event Registry (2021) Zierold S, Kramer R, Erdmann M, Akcetin SL, Maier AM, Koenig A, Theurich S, et al. Conference contribution Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases (2021) Zaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, et al. Journal article "I Feel I'm in Best Hands with You!": A Survey of Patient Satisfaction in a German University Skin Cancer Centre (2021) Steeb T, Wessely A, Merkl H, Kirchberger M, Bosch-Voskens C, Erdmann M, Heinzerling L, et al. Journal article Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US) (2021) Wildner D, Heinzerling L, Scheulen ME, Kämpgen E, Schuler G, Strobel D, Janka RM, et al. Journal article Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) Kaehler KC, Gutzmer R, Meier F, Zimmer L, Heppt M, Gesierich A, Thoms KM, et al. Journal article Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation (2021) Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling L, Meder B, et al. Journal article NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients (2021) Preusse C, Eede P, Heinzerling L, Freitag K, Koll R, Froehlich W, Schneider U, et al. Journal article Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group (2021) Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, et al. Journal article Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response (2021) Dimitriou F, Zaremba A, Allayous C, Kähler KC, Gerard CL, Festino L, Schäfer S, et al. Journal article Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition (2021) Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, et al. Journal article